Amplia Therapeutics: Granted $2.1 million R&D cash flow loan

Amplia Therapeutics Granted $2.1 million R&D cash flow loan

• Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan
• The $2.1 million will be awarded in two tranches: $1.3m in December this year and $0.8 million in the quarter ending March 31, 2022
• The company says it will use funds to increase work on its second Focal Adhesion Kinase (FAK) inhibitor, AMP886
• This will allow Amplia to evaluate new therapeutic opportunities and prepare preclinical activates designed to support future clinical trials of AMP886
• AmpliaTherapeutics is up 2.9 per cent, trading at 18 cents at 12:40 pm AEDT